Coherus Oncology：利多催化劑密集的時期已然到來 (NASDAQ:CHRS)
· seekingalpha.com
CHRS 正面臨 2026 年下半年至 2027 年上半年的關鍵催化劑，包括 tagmokitug/casdozokitug 的數據公布以及 Loqtorzi 銷售額的增長，此外還有 CCR8 數據的潛在上漲空間。點擊此處閱讀詳情。
Coherus Oncology ( CHRS ) has not experienced a sustained run-up, despite the fact the company is approaching a catalyst-rich period. Given CHRS had five or mor...